Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
P 1 (1)
P 2 (4)
P 3 (1)

Trial Status

Not Yet Recruiting2
Recruiting2
Active Not Recruiting2
Unknown1

Clinical Trials (7)

Showing 7 of 7 trials
NCT06287528Phase 1Recruiting

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

NCT04722848Phase 3Active Not Recruiting

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

NCT04475731Phase 2Active Not RecruitingPrimary

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

NCT06220487Phase 2Recruiting

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

NCT06175702Not Yet Recruiting

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

NCT05931757Phase 2Not Yet RecruitingPrimary

A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL

NCT05466175Phase 2UnknownPrimary

A Study of Olverembatinib in the Treatment of Ph+ ALL

Showing all 7 trials

Research Network

Activity Timeline